2020 Cluster Headache Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Cluster Headache pipeline report presents a comprehensive overview of the research and development of Cluster Headache drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Pre-clinical phase, two drugs in Phase 2 and one drug in Phase 3
As of February 2020, the Cluster Headache pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cluster Headache treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT1B/D receptor agonist; AMPA receptor agonists; Calcitonin gene-related peptide antagonist; Nitric oxide synthase inhibitor; NMDA receptor antagonists; TRPV1 receptor agonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cluster Headache drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Cluster Headache pipeline drugs profiled in the report include- CLE-500, Ketamine hydrochloride, sumatriptan, galcanezumab, MTR-108 (Raviclust), zucapsaicin, zolmitriptan
As of February 2020, the Cluster Headache pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cluster Headache treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT1B/D receptor agonist; AMPA receptor agonists; Calcitonin gene-related peptide antagonist; Nitric oxide synthase inhibitor; NMDA receptor antagonists; TRPV1 receptor agonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cluster Headache drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Cluster Headache development
- Cluster Headache pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Cluster Headache pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Cluster Headache pipeline candidates included
- Business overview and snapshot of all companies involved in Cluster Headache pipeline are included
- Latest market and pipeline developments are provided in the report
Cluster Headache pipeline drugs profiled in the report include- CLE-500, Ketamine hydrochloride, sumatriptan, galcanezumab, MTR-108 (Raviclust), zucapsaicin, zolmitriptan
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Cluster Headache Condition
2.3 Cluster Headache Pipeline Snapshot, 2020
2.4 Companies investing in Cluster Headache pipeline therapeutics
2.5 Phase wise Cluster Headache Pipeline Candidates
2.6 Most Researched Mechanism of Action of Cluster Headache Pipeline Products
2.7 Route of Administration of Cluster Headache Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 CCH Pharmaceutical Overview, Contacts and ASD Pipeline Drugs
3.2 Clexio Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Crossject SA Overview, Contacts and ASD Pipeline Drugs
3.4 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.5 TrioxBio Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Winston Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Zosano Pharma Corp Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 CLE-500 Drug Details
4.1.1 CLE-500 Current Status
4.1.2 CLE-500 Drug Overview
4.1.3 CLE-500 Mechanism of Action
4.1.4 CLE-500 Licensing/Collaboration Companies
4.1.5 CLE-500 Clinical Trials
4.2 Ketamine hydrochloride Drug Details
4.2.1 Ketamine hydrochloride Current Status
4.2.2 Ketamine hydrochloride Drug Overview
4.2.3 Ketamine hydrochloride Mechanism of Action
4.2.4 Ketamine hydrochloride Licensing/Collaboration Companies
4.2.5 Ketamine hydrochloride Clinical Trials
4.3 sumatriptan Drug Details
4.3.1 sumatriptan Current Status
4.3.2 sumatriptan Drug Overview
4.3.3 sumatriptan Mechanism of Action
4.3.4 sumatriptan Licensing/Collaboration Companies
4.3.5 sumatriptan Clinical Trials
4.4 galcanezumab Drug Details
4.4.1 galcanezumab Current Status
4.4.2 galcanezumab Drug Overview
4.4.3 galcanezumab Mechanism of Action
4.4.4 galcanezumab Licensing/Collaboration Companies
4.4.5 galcanezumab Clinical Trials
4.5 MTR-108 (Raviclust) Drug Details
4.5.1 MTR-108 (Raviclust) Current Status
4.5.2 MTR-108 (Raviclust) Drug Overview
4.5.3 MTR-108 (Raviclust) Mechanism of Action
4.5.4 MTR-108 (Raviclust) Licensing/Collaboration Companies
4.5.5 MTR-108 (Raviclust) Clinical Trials
4.6 zucapsaicin Drug Details
4.6.1 zucapsaicin Current Status
4.6.2 zucapsaicin Drug Overview
4.6.3 zucapsaicin Mechanism of Action
4.6.4 zucapsaicin Licensing/Collaboration Companies
4.6.5 zucapsaicin Clinical Trials
4.7 zolmitriptan Drug Details
4.7.1 zolmitriptan Current Status
4.7.2 zolmitriptan Drug Overview
4.7.3 zolmitriptan Mechanism of Action
4.7.4 zolmitriptan Licensing/Collaboration Companies
4.7.5 zolmitriptan Clinical Trials
5. LATEST CLUSTER HEADACHE PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Cluster Headache Condition
2.3 Cluster Headache Pipeline Snapshot, 2020
2.4 Companies investing in Cluster Headache pipeline therapeutics
2.5 Phase wise Cluster Headache Pipeline Candidates
2.6 Most Researched Mechanism of Action of Cluster Headache Pipeline Products
2.7 Route of Administration of Cluster Headache Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 CCH Pharmaceutical Overview, Contacts and ASD Pipeline Drugs
3.2 Clexio Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Crossject SA Overview, Contacts and ASD Pipeline Drugs
3.4 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.5 TrioxBio Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Winston Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Zosano Pharma Corp Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 CLE-500 Drug Details
4.1.1 CLE-500 Current Status
4.1.2 CLE-500 Drug Overview
4.1.3 CLE-500 Mechanism of Action
4.1.4 CLE-500 Licensing/Collaboration Companies
4.1.5 CLE-500 Clinical Trials
4.2 Ketamine hydrochloride Drug Details
4.2.1 Ketamine hydrochloride Current Status
4.2.2 Ketamine hydrochloride Drug Overview
4.2.3 Ketamine hydrochloride Mechanism of Action
4.2.4 Ketamine hydrochloride Licensing/Collaboration Companies
4.2.5 Ketamine hydrochloride Clinical Trials
4.3 sumatriptan Drug Details
4.3.1 sumatriptan Current Status
4.3.2 sumatriptan Drug Overview
4.3.3 sumatriptan Mechanism of Action
4.3.4 sumatriptan Licensing/Collaboration Companies
4.3.5 sumatriptan Clinical Trials
4.4 galcanezumab Drug Details
4.4.1 galcanezumab Current Status
4.4.2 galcanezumab Drug Overview
4.4.3 galcanezumab Mechanism of Action
4.4.4 galcanezumab Licensing/Collaboration Companies
4.4.5 galcanezumab Clinical Trials
4.5 MTR-108 (Raviclust) Drug Details
4.5.1 MTR-108 (Raviclust) Current Status
4.5.2 MTR-108 (Raviclust) Drug Overview
4.5.3 MTR-108 (Raviclust) Mechanism of Action
4.5.4 MTR-108 (Raviclust) Licensing/Collaboration Companies
4.5.5 MTR-108 (Raviclust) Clinical Trials
4.6 zucapsaicin Drug Details
4.6.1 zucapsaicin Current Status
4.6.2 zucapsaicin Drug Overview
4.6.3 zucapsaicin Mechanism of Action
4.6.4 zucapsaicin Licensing/Collaboration Companies
4.6.5 zucapsaicin Clinical Trials
4.7 zolmitriptan Drug Details
4.7.1 zolmitriptan Current Status
4.7.2 zolmitriptan Drug Overview
4.7.3 zolmitriptan Mechanism of Action
4.7.4 zolmitriptan Licensing/Collaboration Companies
4.7.5 zolmitriptan Clinical Trials
5. LATEST CLUSTER HEADACHE PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
